Results 231 to 240 of about 128,640 (296)

Impact of Glucagon-Like Peptide-1 Receptor Agonists on Knee Arthroplasty Outcomes. [PDF]

Indian J Orthop
Zaffar H, Imran MA, Rushd F.
europepmc   +1 more source

Glucocorticoids and HPA axis regulation in the stress–obesity connection: A comprehensive overview of biological, physiological and behavioural dimensions

Clinical Obesity, Volume 15, Issue 2, April 2025.
Summary Chronic stress, characterized by increased long‐term exposure to the glucocorticoid hormone cortisol, is increasingly linked to obesity development. Still, various knowledge gaps persist, including on underlying pathophysiological mechanisms. The aim of the current review is to provide the latest insights on the connection between stress and ...
Robin Lengton, Myrte Schoenmakers, Brenda W. J. H. Penninx, Mariëtte R. Boon, Elisabeth F. C. van Rossum   +4 more
wiley   +1 more source

Glucagon-like peptide-1 agonists' effects on glycemic control, weight loss, and beta cells function in type 1 diabetes. [PDF]

Front Endocrinol (Lausanne)
Mirghani HO, Albishi L, Alblewi SM.
europepmc   +1 more source

Efficacy and safety of switching to iGlarLixi from premixed insulin therapy in patients with type 2 diabetes: A real‐world experience

Diabetic Medicine, EarlyView.
Abstract Aims Fixed‐ratio combinations such as iGlarLixi are recommended over premixed insulin as first‐line injectable therapy for type 2 diabetes mellitus (T2DM), yet real‐world evidence on transitions from premix to iGlarLixi remains limited. This study aimed to evaluate the efficacy and safety of switching from premixed insulin to iGlarLixi in a ...
Chun‐Jui Huang, Shun‐Jie Yang, Cheng‐Pin Cheng, Chun‐Hsing Lin, Ya‐Chun Lee, Harn‐Shen Chen   +5 more
wiley   +1 more source

Assessment of thyroid cancer risk associated with glucagon-like peptide 1 receptor agonist use. [PDF]

Diabetes Obes Metab
Vilsbøll T, Stellfeld M, Aroda VR, Dandanell S, David JP, Kristiansen CTP, Rasmussen S, Roberts FL, Hegedüs L.   +8 more
europepmc   +1 more source

Glucagon-like peptide-1 analogs reduce alcohol intake

Endocrine Abstracts
Maurice O'Farrell, Faisal I. Almohaileb, Carel W. le Roux   +2 more
openaire   +2 more sources

Clinically significant hypoglycaemia in hospitalised adults: A multicentre study of 1205 episodes in the United Kingdom

Diabetic Medicine, EarlyView.
Abstract Introduction and Objectives Inpatient hypoglycaemia is a serious complication of diabetes therapy, yet real‐world data on clinically significant episodes remain limited. The objectives of this study are (1) to describe the clinical and biochemical characteristics of clinically significant inpatient hypoglycaemia across multiple NHS sites, (2 ...
Charles Page, Mariam Idrissi, Sam Sherratt‐Mayhew, Aashritha Buchipudi, Amanda Ling Jie Yee, Kalyaani Persad, Aqeelah Khatoon, Amrit Rakkar, Amynta Arshad, Alexandra Lubina Solomon, Rajeev Raghavan, Lakshmi Rengarajan, Ahmed Iqbal, Pratik Choudhary, Aspasia Manta, Punith Kempegowda, DEVI Collaboration   +16 more
wiley   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists for Arthritis and Osteoarthritis. [PDF]

Cureus
Nashwan AJ.
europepmc   +1 more source

The burden of diabetic foot ulcers in a multi‐ethnic Asian cohort

Diabetic Medicine, EarlyView.
Abstract Aims Diabetic foot ulcers (DFUs) are a major source of morbidity among individuals with diabetes mellitus (DM), imposing a substantial burden on healthcare systems. Our institution established a multidisciplinary service aiming to facilitate early specialist intervention for DFU management.
Zongwen Wee, Yong Mong Bee, Sueziani Binte Zainudin   +2 more
wiley   +1 more source

Thyroid Cancer Risk in Patients With Type 2 Diabetes Taking Glucagon-Like Peptide 1 Receptor Agonists. [PDF]

OTO Open
Sciscent BY, Eberly HW, Lorenz FJ, Goldrich D, Goyal N, Goldenberg D.   +5 more
europepmc   +1 more source